Monogram Bioscience investors had early warning.
Many Monogram Bioscience investor were mighty upset when I first revealed the maraviroc allegations on April 30.
That isn't surprising.
While maraviroc is too small to move Pfizer stock, Monogram Bioscience depends on the launch of maraviroc, so they can sell a blood test to determine if a patient falls into the category that should be treated with the Pfizer drug.
Almost a month has now passed with more revelations.
So what has happened with Monogram Bioscience stock?
Well, investors who sold after my first revelation have saved a bundle.
The stock has since experienced heavy selling pressure and dropped sharply on increasing volume.
Investors who didn't sell have so far lost about 20% of their money in less than a month.
The market has spoken.
And while a technical chart analysis would indicate that the stock is getting ready for an upside move, no one knows what will be revealed next week.
That's the downside with technical analysis.